Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > Testing, Testing, Testing

<< Previous

Bullboard Posts

Next >>

Post by Smokey1958on Jan 21, 2022 7:06am

238 Views

Post# 34341190

Testing, Testing, Testing

In spite of the best efforts of many, the pandemic is unlikely to become endemic anytime soon. For that reason alone AcuVid is still in the game. Presuming Rob would not again risk an estimated timeframe misstep there are very few days left in January ...essentially sometime next week for an NR on the final submission to the FDA. The wait and anticipation should finally be over ...let's go THRM!!!

https://globalnews.ca/news/8526416/omicron-herd-immunity-covid/

The Omicron variant, which is spreading far faster than previous versions of the coronavirus, is not likely to help countries achieve so-called herd immunity against COVID-19, in which enough people become immune to the virus that it can no longer spread, leading disease experts say.

https://nationalpost.com/pmn/health-pmn/u-s-preparing-for-possible-future-covid-variants-white-house

“We’re prepared. We’re increasing the production of tests. We’re increasing the production of masks,” Klain said in the interview that was taped on Wednesday.